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ABSTRACT
The Role of the Striatal Neuropeptide Neurotensin in the
Methamphetamine-induced Neural Injury in Mice
By
Qingkun Liu
Advisor: Professor Jesus A. Angulo

Methamphetamine (METH) is a widely abused psychostimulant that induces neurotoxicity to
several brain regions, including the striatum. Similar to dopamine (DA) in chemical structure,
METH can be transported into DA pre-synaptic terminals, evoking neurodegeneration in DA
terminals and post-synaptic striatal neurons. Despite the critical role of DA in METH-induced
neurodegeneration, no pharmaceutical therapeutics has been approved for these conditions. It is
therefore essential to investigate endogenous factors regulating the dopaminergic system. The
neuropeptide neurotensin has emerged as a potential modulator of METH-induced striatal
neurodegeneration mainly due to its intimate interactions with dopamine in the striatum.
In this study, we investigated the role of the neuropeptide neurotensin on METH-induced striatal
neurodegeneration in mice. We observed that a single injection of METH (30 mg/kg, ip) induced
the loss of approximately 15% of striatal neurons. An agonist of the neurotensin receptor 1
(PD149163, ip) attenuated the METH-induced striatal neuron apoptosis in a dose-dependent
manner, while exerted no effect on METH-induced dopamine terminal degeneration. Utilizing
quantitative Real Time PCR, we showed that METH also up-regulated neurotensin gene
expression by 96% in stratal neurotensin mRNA. These data demonstrate that neurotensin
modulates METH-induced striatal apoptosis through neurotensin receptor 1 (NTR1) in the
striatum. In addition, NTR1 agonist attenuated METH-induced hyperthermia and can also
attenuate the striatal apoptosis independent of such body temperature regulatoin. To further
investigate the corresponding mechanisms, we assessed its effect on glial cell activation, nitric
oxide accumulation and DARPP32 phosphorylation in the striatum, which are all believed to
iv

aggravate METH-induced neurodegeneration. We observed that the NTR1 agonist attenuated the
effects of METH on each of these three biomarkers. Our results also show that the NTR1 agonist
alone caused decrease in phosphorylation of DARPP32 at Thr34, while NTR1 antagonist
(SR48692) per se increased the phosphorylation of DARPP32 at Thr34. Since the DARPP32
phosphorylation pathway is responsible for interpreting signals to striatal projection neurons,
neurotensin possibly modulates its phosphorylation through regulation of DA and glutamate
neurotransmission. Finally, the agonist of neurotensin, PD149163, may be considered as a
potential therapeutic for treatment of METH-induced neurotoxicity. (Supported by R01
DA020142 from NIDA/NIH)
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We detected the body core temperature of mice with a BAT-12 thermometer coupled to RET-3
mouse rectal probe.
Aim 2f: To investigate whether activation of neurotensin receptor attenuates the METHinduced apoptosis independent of body temperature regulation
Hypothesis: we proposed that neurotensin receptor 1 agonist, PD149163, attenuate METHinduced striatal apoptosis independent of its body temperature regulation.
Rationale: in the brain, hypothalamus but not striatum controls the body temperature and
neurotensin exert the effects to regulate body temperature through neurotensin receptor 1 which
also locates in the hypothalamus. Therefore it is possible to disable function of neurotensin
receptor 1 on body temperature regulation through intrastriatal infusion. And since neurotensin
receptor 1 can regulate dopamine and glutamate neurotransmission in the striatum, it is potential
that it attenuates the METH-induced striatal apoptosis independent of body temperature

xix

regulation.

xx

CHAPTER 1. INTRODUCTION
Methamphetamine (N-Methyl-O-phenylisopropylamine, “METH”) is an analog of amphetamine
(alpha-Methyl-phenethyl-amine) used as a psychostimulant with potent sympathetic and CNS
action (Davidson et al., 2001; Sulzer et al., 2005). Although both molecules are similar, METH
is more lipophilic and crosses the blood-brain barrier more readily, making the molecule more
potent and toxic than its parent compound (Meredith et al., 2005).
1. Epidemiology of Methamphetamine abuse
As a synthetic psychostimulant, METH can be injected, smoked, snorted, ingested or
transrectally administered (Anglin et al., 2000; Cantrell et al., 2006). The current METH use
epidemic in the U.S. began in the mid-1980s on the West Coast and has since spread across the
western states to the Midwest, southern states, and the East Coast (Rose and Grant, 2008). While
METH use has been reported on every continent, the vast majority of METH users reside in East
and South-East Asia as well as North America (United Nations Office on Drugs and Crime,
2013). In China, the largest METH market in the world, the prevalence of METH use among
new drug users is estimated at 5.6%, which is surpassed only by heroin use among new users (Lu
et al., 2008). In North America, Mexico has become the largest producer of METH as a result of
restrictions on precursor chemicals in the U.S. and Canada (Ritsner, 2011), but the west coasts of
the U.S. and Canada have also been greatly affected by METH use (Maxwell and Rutkowski,
2008; National Drug Intelligence Center, 2006). The estimated annual prevalence rate in the
general U.S. population for METH use was 1.4% in 2006 (Maxwell and Rutkowski, 2008).
2. Social and financial costs of Methamphetamine abuse
METH use poses significant public health challenges and economic burdens. In a recent
economic assessment, METH use cost the United States $23.4 billion in 2005 alone (Gonzales,
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2010). This expenditure included costs associated with morbidity and mortality, criminal justice
and social welfare services, environmental damage from METH chemical production, and, most
significantly, lost productivity and reduced quality of life (Nicosia, 2009). Tremendous social
harms associated with METH are experienced by neighborhoods, including METH production,
trafficking and dealing, and related systemic violence. The manufacture and production of
METH require chemicals that are explosive, corrosive, and flammable and that can result in
burns, respiratory ailments, poisoning, and fires (Gonzales et al., 2010). Further, manufacturing
of METH in automobiles increases the likelihood of spilling toxic wastes and chemicals into the
environment and polluting ground water sources (Holton, 2001).
3. METH-induced neurodegeneration
Compounding these challenges, a considerable body of evidence indicates that METH abuse can
lead to serious and persistent cognitive, psychiatric, and neurological dysfunction in the user, and
can negatively affect the development of children exposed to METH in utero and the well-being
of children raised by METH-addicted parents (Chandler, 2010). Despite severe METH abuse in
the U.S. and worldwide, we do not fully understand the mechanisms through which METH
triggers neurodegeneration and dysfunction of the central nervous system. Such understanding
could contribute to the development of medications to treat the consequences of neurotoxicity.
Although METH abuse leads to dysfunction in many other areas of the brain, including the
prefrontal cortex and hippocampus (Graham et al., 2008; Kuczenski et al., 2007), this project
focused on the striatum, the major component of the basal ganglia, given its psychomotor
behavioral control function. The striatum controls a broad range of behaviors including learning,
motivation, habit-forming, and addictive behaviors, and experiences severe neurodegeneration
2

with METH administration (Kawagushi, 1997; Koob and Le Moal, 1997; Balleine et al., 2007).
3.1 Striatal neurodegeneration due to METH use
3.1.1 Striatum structure and function
The striatum, also known as the neostriatum or striate nucleus, is a subcortical part of the
forebrain. It is the major input station of the basal ganglia system. Most cortical areas provide
inputs to the basal ganglia, which in turn provide outputs to the brain systems involved in the
generation of behaviors. The vast majority of the striatal neurons are medium spiny projection
neurons, the activity of which is stimulated as follows: 1) excitatory inputs from the cerebral
cortex and thalamus with glutamate; and, 2) feedback pathways from the substantia nigra pars
compacta (SNc) by dopaminergic neurons (Kawaguchi et al., 1997; DiFiglia et al., 1976; Wilson
and Groves, 1980; Bishop et al., 1982; Kemp and Powell, 1971). Essentially all the functions
ascribed to the striatum are intimately linked to their rich dopaminergic innervation, which
originates in the midbrain SNc (Somogyi et al., 1981). In addition to the spiny projection neurons
that comprise up to 97.7% of striatal neurons in rodents (Rymar et al., 2004), the striatum is
composed of one type of cholinergic interneuron and electrophysiologically distinct GABAergic
interneurons that extend axons within but not outside the striatum (Kawaguchi, 1993; Kawaguchi
et al., 1995; Tepper and Bolam, 2004; Tepper et al., 2008). Striatal cholinergic neurons, which
use acetylcholine as a neurotransmitter, constitute an important type of interneuron (Bolam et al.,
1984; Wilson et al., 1990; Kawaguchi, 1993). Although acetylcholine release is clearly important
to striatal function, the neuroanatomical substrates by which this is regulated have been difficult
to identify (Paxinos, 2004).
The second major subtype of striatal interneurons is characterized morphologically as a medium3

sized aspiny neuron that uses GABA as the main neurotransmitter. Although few in number,
striatal GABAergic interneurons play a predominant role in regulating spike timing in the spiny
output neurons through feedforward inhibition (Tepper et al., 2004, 2008). The most abundant
type of GABAergic interneurons expresses the calcium-binding protein parvalbumin (Gerfen et
al., 1985; Cowan et al., 1990; Kita et al., 1990). A second class of GABAergic interneurons coexpresses somatostatin, neuropeptide Y, and nitric oxide synthetase (Vincent et al., 1983; Smith
and Parent, 1986; Pasik et al., 1988; Dawson et al., 1991). In addition to the neurons, glial cells,
mainly astrocytes and microglia, support and protect neurons as innate immune cells inside the
striatum (Jesse et al., 1980; Gourine, et al., 2010).
Given its similar molecular structure to dopamine (DA), METH enters the dopamine axons of
striatum via dopamine transporters (DAT) and passive diffusion (Iversen, 2006). Within these
neurons, METH enters synaptic vesicles through VMAT-2 and causes DA release into the
cytoplasm via changes in pH balance. By reversing transport of DA by DAT into the synaptic
cleft from the cytoplasm, METH dramatically increases the concentration of DA between the
synapses of DA terminals and striatal neurons (Sulzer et al., 2005).
3.1.2 Neuronal degeneration of striatum after METH abuse
The neurotoxic effects of METH on striatal dopaminergic neurons are suggested to be mediated
by excess DA release (Stephans and Yamamoto, 1994). Numerous studies have confirmed this
hypothesis and suggested that once DA is released from synaptic vesicles to the cytoplasm of
DA terminals by METH, DA then auto-oxidizes into potentially toxic chemicals, including
superoxide radicals, hydroxyl radicals, hydrogen peroxide and DA quinone (DAQ) (Acikgoz et
al., 1998; Kita et al., 1999; LaVoie and Hastings, 1999; Lazzeri et al., 2007; Miyazaki et al.,
4

2006). These reactive oxygen species (ROS) in the DA terminals then diffuse from the dopamine
terminals to the post-synaptic neurons (i.e. MSNs) and damage them by reacting with
proteasomes, mitochondria and DNA, leading to protein misfolding, proteasomal and
mitochondrial dysfunction and eventually programmed cell death (Halliwell, 1992; Andersen,
2004).
Our lab has discovered that 25% of the projecting neurons in the striatum experienced apoptosis
after acute METH administration in mice. Although new neurons were generated after apoptosis,
the function of these newly generated neurons is unknown (Tulloch et al., 2011). In addition,
METH induces the neurotoxicity of dopamine terminals from the nigral-striatal pathway marked
by a decrease of at least 50% in Tyrosine hydroxylase (TH) level, increased synapse DA level
and reduced DAT after acute METH administration in mice (Yu et al., 2002; Zhu et al., 2005).
These three biomarkers of the DA terminal contribute to the DA neurotransmission to striatal
medium spiny neurons differentially. Tyrosine hydroxylase is the rate-limiting enzyme that
catalyzes the biosynthesis of DA from tyrosine (Luvone et al., 1978; Daubner et al., 2011). Due
to decreased levels of this enzyme, DA productivity is dramatically reduced as demonstrated by
lower DA levels inside the striatum (Kogan et al., 1976; Krasnova et al., 2009). DAT normally
transport the released DA from synapses back to the DA terminals (Kahlig et al., 2003). By
doing this, DAT prevent the over excitement of the medium spiny projecting neurons. After the
METH administration, instead of recycling the dopamine, DAT transports more DA outside the
cytoplasm to over excite the striatal neurons (Wilson, 1996). As a result, DA as the
neurotransmitter accumulates between the synapses, forming a nigral-striatal pathway.

5

3.2. Potential mechanisms of METH-induced neurodegeneration
DA neurotransmission may play a significant role in METH-induced neurodegeneration of DA
terminals and striatal neuronal apoptosis. Other factors are also involved in this process,
including hyperthermia, oxidative stress, nitric oxide, glial cell activation, and the DARPP32
(dopamine and cAMP-regulated phosphoprotein, molecular weight=32 kD) pathway.
3.2.1 Neurotransmission disruption by METH and DARPP32 pathway
METH interrupts several neurotransmitters in the striatum, including dopamine, glutamate and
nitric oxide. The striatal medium spiny projecting neurons as main input and output neurons in
the striatum adjust their function according to these three neurotransmitters through their
receptors from SNc, the prefrontal cortex and interneurons of the striatum (Steiner and Tseng,
2010). After entering the neurons, METH increases release of both dopamine and nitric oxide
into the striatum. The dopamine also increases the glutamate release, thereby causing signal
transmission dysfunction of the striatum. METH increases the dopamine release by reversing the
transmission of dopamine out of the cytoplasm via the dopamine transporter, which not only
over-excites the striatal projecting neurons, but also up regulates the glutamate input from the
prefrontal cortex, causing excitotoxic damage (Sulzer et al., 2005; Abekawa et al., 1994;
Baldwin et al., 1993; Mark et al., 2004; Marshall et al., 1993). Both dopamine and glutamate
manipulate function of striatal neurons through the DARPP32 pathway (Greengard, 2001).
DARPP32 is highly concentrated in the striatum. The striatal medium spiny neurons that contain
DARPP32 are the only neurons that convey an efferent pathway from this major brain region.
These neurons interpret information entering the striatum from many other regions in the brain,
and DARPP32 plays a central role in this integration process. Activation of dopamine receptors 1

6

by DA causes an increase in the level of cAMP, the activation of PKA, and the phosphorylation
of threonine-34 of DARPP32. This pDARPP32 is activated to inhibit protein protease 1, which
controls the state of phosphorylation and activities of numerous physiologically important
substrates, including neurotransmitter receptors, voltage-gated ion channels, ion pumps, and
transcription factors (Figure 1).

7

Figure 1. Signaling pathways in the neostriatum. Activation of the dopamine receptors D1 by
dopamine stimulates the phosphorylation of DARPP-32 at Thr-34. This is achieved through a
pathway involving the activation of adenylyl cyclase, the formation of cAMP, and the activation
of PKA. Activation by dopamine of the D2 subclass of dopamine receptors causes the
dephosphorylation of DARPP-32 through two synergistic mechanisms as indicated with green
and orange arrows. In response to glutamate, activation of the AMPA and NMDA subclasses of
glutamate receptor increases intracellular calcium and the activity of PP2B, and causes the
dephosophorylation of DARPP-32 on Thr-34. All other neurotransmitters that have been shown
to act directly to alter the physiology of dopaminoceptive neurons also alter the phosphorylation
state of DARPP-32 on Thr-34 through the indicated pathways. Neurotransmitters that act
indirectly to affect the physiology of these dopaminoceptive neurons also regulate DARPP-32
phosphorylation: e.g., neurotensin and cholecystokinin (CCK). (Adapted from Paul Greengard,
2001.)

Deletion of the DARPP-32 gene in animals has been shown to significantly reduce biological
effects of all drugs of abuse (Byrne and Roberts, 2009). Drugs of abuse, all of which affect the
physiology of these neurons, also regulate the state of DARPP-32 phosphorylation (Greengard,
2001). Since METH could up regulate the level of both dopamine and glutamate, which exert
opposite regulations on this pathway, we hypothesized that the delicate balance of this DARPP8

32 phosphorylation and dephosphorylation would shift and trigger the neurodegeneration of the
striatal neurons through protein phosphatase 1 (PP1).
Nitric Oxide (NO), a small molecular neurotransmitter, may also contribute to neurotoxicity by
METH. The first evidence comes from the finding that after METH administration, the NO level
indicated by 3-NT, an indirect marker for NO, has been increased by nearly seven times (Zhu et
al., 2005). In addition, 7-nitroindazole and ILH, inhibitors of the NO-producing enzymes in
neurons and microglia, respectively, could both significantly reduce the apoptosis of striatal
neurons. The mechanism behind these phenomena may comprise three components. First, NO is
found to increase DARPP-32 phosphorylation in striatal MSNs of brain slices through the NOcGMP-PKG pathway (Tsou et al., 1993; Nishi et al., 2005), which may cause degeneration of
striatal neurons.
Second, NO may exert its biological effect by regulating the glutamate neurotransmission. It is
generally accepted that NO signaling can amplify excitatory neurotransmission at glutamatergic
synapses in numerous brain regions (Garthwaite, 2008). Studies using reduced striatal
preparations have shown that NO can inhibit glutamate transporters, leading to increases in
extracellular glutamate concentrations. In vivo microdialysis studies in rats have also shown that
intrastriatal infusion of both NO synthase (NOS) substrate and NO generators increased local
glutamate efflux up to two-fold over basal levels (Guevara-Guzman et al., 1994; West and
Galloway, 1997).
In addition, NO also contributes to regulation of dopamine release. Numerous studies performed
in rats, mice and hamsters have demonstrated that endogenous NO produced via intrastriatal
substrate (L-arginine) infusion facilitates DA efflux in vitro (Zhu and Luo, 1992; Liang and
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Kaufman, 1998) and in vivo (Strasser et al., 1994; West and Galloway, 1997). The upregulation
of dopamine release will undoubtedly augment the METH-induced dopamine overflow and thus
cause further degeneration and over excitation of post-synaptic neurons, such as striatal medium
spiny neurons.
3.2.2 METH-induced hyperthermia
METH-induced hyperthermia is well recognized as a significant contributing factor to
neurodegeneration in rodents. In rats, temperature may reach above 40°C after each injection of
amphetamine (Burrows and Meshul, 1999; Burrows et al., 2000; Kokoshka et al., 2000;
Sandoval et al., 2000) where hyperthermia-induced death can occur. Chronic METH
(20mg/kg/day×7 days) is also hyperthermic for the first 2 to 3 days, and can also result in death
(Davidson et al., 2001). It has been shown that increased body temperature can induce oxidative
stress in many systems (Lin et al., 1991; Omar et al., 1987; Skibba et al., 1991) in addition to
neurodegeneration from cerebrovascular damage; this may be a mechanism whereby
hyperthermia mediates neurodegeneration. METH-induced mild hyperthermia is an important
component of METH-induced dopaminergic neurotoxicity (Evan L Riddle et al., 2006), as
evidenced by the high correlation between the degree of changes in the DA system, or the degree
of neurodegeneration, and the degree of hyperthermia (Bowyer et al., 1994; Sandoval et al.,
2000; Davidson et al., 2001). In addition, prevention of hyperthermia attenuates METH-induced
DA decrease and loss of DA uptake in the striatum (Bowyer et al., 1992; 1993; 1994). Due to the
significant role of hyperthermia in METH-induced neurodegeneration, it is necessary to detect
the effect of any drug candidate on body temperature regulation to rule out hyperthermia as a
contributing factor to neurochemical and other changes.
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3.2.3 Role of reactive oxygen species and nitric oxide (NO)
Reactive Oxygen Species (ROS) are chemically reactive molecules containing oxygen, which
include superoxide, hydroxyl radical and peroxide (Devasagayam et al., 2004). ROS form as a
natural byproduct through endogenous mechanisms such as mitochondrial respiration or via
exogenous agents that augment glutamate activity and auto-oxidative processes in brain tissues
(Bindoli et al., 1992; Cadet and Brannock, 1998). In several studies, overproduction of ROS by
METH administration has been found to induce DA terminal neurodegeneration and striatal
neuron apoptosis (Potashkin and Meredith, 2006; Fitzmaurice et al., 2006; Stone et al., 1989).
METH-induced depletion of DA and 5-HT in the rat striatum are exacerbated by the superoxide
dismutase (SOD) inhibitor, diethyldithiocarbamate (De Vito and Wagner, 1989). The role of
ROS in METH-induced neurotoxicity is also supported by homozygous transgenic mice, which
overexpress copper/zinc superoxide dismutase (CuZnSOD). These transgenic mice are nearly
resistant to METH-induced neurotoxicity of the DA terminal, increase in caspase-3 activity and
neuronal death (Deng and Cadet, 2000; Cadet et al., 1994; Hirata et al., 1996; Epstein et al.,
1987).
Through reaction with ROS, nitric oxide also contributes to METH-induced neurodegeneration.
There are three types of nitric oxide synthase, neuronal NOS (nNOS), immunological NOS
(iNOS), and endothelial NOS (eNOS) (Nathan and Xie, 1994; Bredt and Snyder, 1994).
Pharmacological inhibition of nNOS or deletion of this gene protects DA terminals against
METH-induced toxicity (Itzhak and Ali, 1996; Imam et al., 2001a, 2001b). In addition, nNOS
knockout mice (nNOS -/-) are protected from METH-induced dopaminergic neurotoxicity
(Itzhak et al., 1998). These studies indicate the role of NO in METH-induced dopaminergic
damage. Indeed, NO reacts with superoxide radicals (O2-) to produce Peroxynitrite (OONO-), a
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potent oxidant (Radi et al., 1991). We have reported that the METH treatment that causes
dopaminergic neurotoxicity also induces a six-fold increase of 3-nitrotyrosine (3-NT), an in vivo
biomarker for OONO- production in the mouse striatum (Zhu et al., 2009). In addition, both
nNOS knockout mice and CuZnSOD transgenic mice resisted DA terminal damage induced by
METH. These results suggest the involvement of NO and ROS in METH-induced DA terminal
damage. There is also evidence showing that ROS induces neuronal apoptosis in vitro by
reacting with NO (Troy et al., 1996). Combining these findings, it is likely that ROS and NO are
closely correlated in their chemical reaction of producing peroxynitrite that may trigger METHinduced neurotoxicity.
3.2.4 Glial cells contribute to neurodegeneration
Glial cells are non-neuronal cells that maintain homeostasis, form myelin, and provide support
and protection for neurons in the brain (Kristjan et al., 1980). There are two general types of glia
in the central nervous system: the macroglia class, which consists of astrocytes and
oligodendrocytes, and the microglia class, which consists mainly of microglia and has
macrophage-like properties (Haydon, 2001). Of the macroglia class, astrocytes are highly
numerous and are likely to have many divergent roles. microglia and astrocytes are the two most
abundant glial cells in the brain that monitor neurodamage and inflammation. Microglia are the
resident innate immune cells in the central nervous system and produce a barrage of factors (IL1, TNFα, NO, PGE2, superoxide) that are toxic to neurons. Evidence supports the activation of
microglia in response to environmental toxins, endogenous proteins and neuronal death, resulting
in the production of toxic factors that propagate neuronal injury (Gao et al., 2002; Wu et al.,
2005; Qin et al., 2002; Sanchez-Moreno et al., 2004).
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An increasing number of studies indicate that activated glial cells may also contribute to
neurotoxicity from METH. Using the PET technique, Yoshimoto and colleagues reported that
METH causes microglial activation in the brains of human abusers (Yoshimoto et al., 2008). The
LaVoie laboratory also indicated that microglial activation preceded the appearance of
pathological changes in striatal DA fibers due to METH administration (LaVoie et al., 2004).
The involvement of glial cells in METH toxicity is also supported by tolerance in mice to
neurotoxic effects if the microglial activation is attenuated after METH administration (Thomas
and Kuhn, 2005). Our lab has also shown that astrocytes are activated and peak their activation
three days after METH administration (Zhu et al., 2005). Nevertheless, Sriram also showed that
attenuation of microglial activity alone is not sufficient to protect against METH neurotoxicity,
indicating the need for further study to explore the role of glial cells on METH-induced
neurodegeneration (Sriram et al., 2006).
4. Neurotensin: candidates for neuroprotection
4.1 METH and neuropeptides
The central nervous system uses two main classes of chemical substances for signaling: small
molecule transmitters such as dopamine and glutamate, and neuroactive peptides, which are short
polymers of amino acids (Kandel et al., 2000). There are two types of neurons comprising the
striatum; namely, interneurons and projection neurons. The striatal medium-sized spiny neurons,
i.e., striatal projection neurons that comprise over 90% of striatal neurons, produce several
neuropeptides as neurotransmitters such as substance P and neurotensin. Both striatal projection
neurons and interneurons go through apoptosis after acute METH administration, except for
somatostatin/nNOS/NPY interneurons, the only interneurons producing neuropeptides
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neuropeptide Y and somatostatin (Zhu et al., 2006). Our laboratory has been investigating the
role of endogenous striatal neuropeptides that modulate the METH-induced elevation of
oxidative stress. Striatal neuropeptides are strategically placed to modulate striatal dopaminergic
responses. The striatal neuropeptide substance P synergizes with METH in elevating the
production of nitric oxide (Wang and Angulo, 2011a) and consequently striatal injury (Zhu et al.,
2009). In particular, METH-induced DA overflow initially induces neuropeptide substance P
production in striatal projection neurons, which then activate Somatostatin/nNOS/NPY
interneurons, leading to nitric oxide overproduction, finally triggering neuronal apoptosis.
Interestingly, two other striatal neuropeptides, somatostatin and neuropeptide Y, attenuate the
METH-induced striatal production of nitric oxide (Yarosh and Angulo, 2012; Afanador et al.,
2013).
4.2 Endogenous neuropeptide neurotensin
In addition to substance P, neuropeptide Y, and somatostatin, neurotensin may also play an
essential role in METH-induced striatal neurodegeneration due to its intimate interactions with
dopamine in the striatum. Neurotensin (NT) is a 13 amino acid peptide that was first isolated
from the calf hypothalamus by Carraway and Leeman in 1973. NT derived its name from its
location in the brain and its tendency to cause hypotension in animals when injected peripherally.
The amino acid sequence of neurotensin is Pyr-Glu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-ProTyr-Ile- Leu-OH (Carraway and Leeman, 1975). In the brain, NT is particularly expressed within
the nigrostriatal and mesolimbic dopamine system (Jennes et al., 1982; Leeman and Carraway,
1982) and most of its effects are mediated through the activation of two different G proteincoupled receptor subtypes: neurotensin receptor 1 (NTR1) and neurotensin receptor 2 (NTR2)
(Vincent et al., 1999). Within the basal ganglia, NT is closely associated with the nigrostriatal
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DA and striatopallidal GABA neurons. Its high affinity receptor (NTR1) is widely expressed
(mRNA) on dopaminergic neurons in the substantia nigra while only small amounts of NTR2 are
found in the striatum. In the striatum, NTR1 expression seems associated with the dopaminergic
terminals from the nigral neurons and glutamatergic terminals from cortical inputs (Nicot et al.,
1994; Alexander and Leeman, 1998). The close co-distribution between NT and DA systems
together with the functional evidence that NT modulates dopaminergic signaling both in limbic
and in striatal brain regions have suggested that NT may be implicated in the pathophysiology of
various central nervous system disorders, including schizophrenia, Parkinson’s disease and drug
abuse of cocaine and METH (Nemeroff, 1980; McMahon et al., 2002; Caceda et al., 2006;
Kinkead and Nemeroff, 2006; St- Gelais et al., 2006).
Evidence of neurotensin participating in the psychostimulant-induced physiological phenomenon
has also emerged. For example, early stereotactic experiments demonstrated that neurotensin
produces psychostimulant-like effects following site-specific microinjection in the ventral
tegmental area (VTA) (Kalivas et al., 1983; Kalivas et al., 1981). However, neurotensin
administration in the NAc attenuates amphetamine-stimulated locomotor activity (Ervin et al,
1981; Robledo et al., 1993). These different effects most likely reflect differences in the neurons
influenced by neurotensin signaling in these respective locations. Psychostimulants are also
found to increase neurotensin expression in striatal D1-positive neurons and to elevate
extracellular neurotensin levels in the striatum through a mechanism involving both D1 and
NMDA receptor signaling (Wagstaff et al., 1997). This suggests that neurotensin is released from
D1 positive neurons.
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Neurotensin receptor 1 (NTR1) is the primary neurotensin receptor associated with dopamine
neurons anatomically and also the major neurotensin receptor found in the striatum. Therefore,
most research on neurotensin has emphasized NTR1 activity in the striatum. Several
investigations have demonstrated that systemic delivery of NTR1 agonist PD149163 or
neurotensin analog NT69L attenuates amphetamine-induced hyperactivity or METH selfadministration in rodents. In addition, NT injection into the nucleus accumbens reduces the
responses to psychostimulants (Ervin et al., 1981; Robledo et al., 1993.). Mona Boules also
reported that NT69L, neurotensin analog, blocks cocaine- and D-amphetamine-induced
hyperactivity (Boules et al., 2001). In addition, NT69L blocked the acute locomotor effects of
nicotine, as well as the initiation and expression of sensitization to this stimulant (Fredrickson et
al., 2003. a, b).

The potential mechanism by which NT might be involved in amphetamine activation of D1
positive striatal neurons is shown in Figure 2, below. Psychostimulants have been shown to
increase extracellular levels of striatal NT, and this release involves signaling through both
dopamine D1 and NMDA receptors (Wagstaff et al., 1997). NTR-1 has been localized to both
nigral dopamine and cortical projection neurons, but has not been localized to striatal neurons in
the dorsal striatum (Boudin et al., 1996). NT has been shown to antagonize D2 receptor function
and to enhance amphetamine-evoked increases in extracellular dopamine levels through
antagonism of D2 auto-inhibition under certain circumstances (Diaz-Cabiale et al., 2002; Pehek,
1999). These findings indicate that NT in the striatum will augment dopamine and glutamate
release through NTR1 as shown in figure 2.
Both glutamate and DA neurotransmissions affect DARPP32 phosphorylation pathway in the
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pos-synaptic neurons, e.g. MSNs, which controls numerous physiological function including the
programmed cell death (apoptosis). Glutamate release induced by neurotensin attenuates the
DARPP32 phosphorylation (Figure 1), while dopamine release promotes such phosphorylation.
Although neurotensin augments dopamine and glutamate neurotransmission modulating the
phosphorylation of DARPP32, no information about the effect of neurotensin in DARPP32
phsophorylation in vivo is available. We intend to assess this effect by detecting the levels of
phosphorylated DARPP32 and total DARPP32 affected by METH and NTR1 agonist in the
striatum.
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Figure 2. Neurotensin regulates dopamine and glutamate neurotransmission in the
striatum. The release of neurotensin from D1-positive striatal neurons activates the NTR-1 in
both subtantia nigra dopamine neurons and corticostriatal neurons, which augment the release of
dopamine and glutamate and attenuate D2 receptor activation to inhibit the dopamine and
glutamate release (adapted from Dobner, 2001).

Besides regulation of DA and glutamate neurotransmission, Neurotensin also reduces body
temperature by NTR1. Rise of body temperature induced by METH contributes to dopaminergic
neurotoxicity (Riddle et al., 2006) in the striatum, with the evidence of the correlation between
the changes in the DA system (the degree of neurodegeneration) and hyperthermia (Davidson et
al., 2001). These findings show that neurotensin is likely to attenuate METH-induced
hyperthermia through the NTR1 signaling. Despite this circumstantial information, no evidence
indicates that neurotensin attenuates METH-induced hyperthermia through systemic delivery.
One of the goals is to test the effect of NTR-1 on METH-induced hyperthermia.
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As described above, METH administration also induces glial cell activation and Nitric oxide
accumulation in the striatum, which causes neurodegeneration through neurotoxic proinflammatory factors and oxidative stress. Since METH-induced striatal apoptosis precedes the
glial cell activation in the striatum, it is possible that glial cell activation is triggered by METHinduced neuron apoptosis. We assumed that neurotensin attenuates METH-induced glial cell
activation and the corresponding over-production of NO from the glial cell activation.

To summarize, we assume that neurotensin probably attenuates METH-induced neurotoxicity,
with characterization of reduced striatal neuron apoptosis through DARPP32 pathway, glial cell
activation, NO production and body temperature regulation in the striatum.
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CHAPTER 2. MATERIAL AND METHODS
1. Animal Care and Use
All procedures involving animal use were approved by the Institutional Animal Care and Use
Committee of Hunter College, City University of New York (JAA-Neurotensin, approved
10/09/013) and were performed in accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals (2011). The Hunter College Animal Facility is
certificated by the American Association for Accreditation of Laboratory Animal Care
(AAALAC). 702 ICR male mice between 12 and 14 weeks old (Taconic; Germantown, NY)
were housed individually on a 12-hour light/dark cycle with ad libitum access to food and water.
The mice were habituated for at least two weeks prior to commencement of intraperitoneal (i.p.)
drug administration.
2. Drug Preparation and Treatment
Neurotensin NTR1 receptor agonist, PD149163 (≥95%; Sigma; St. Louis, MO), a Neurotensin
analog (8-13), Lys- (psiCH2NH)-Lys-Pro-Trp-Terleu-Leu-OEt, was dissolved in 10mM PBS to
0.4mg/ml concentration and administered to mice as 0.5mg/kg, 1mg/kg and 2mg/kg of body
weight through intraperitoneal injection.
(+)-Methamphetamine hydrochloride (Sigma; St. Louis, MO) was dissolved in 10mM
phosphate-buffered PBS, pH 7.4 (PBS). Groups of mice were injected intraperitoneally with
either one bolus METH dose of 30 mg/kg of body weight or in a matching volume of PBS.
For perfusion, animals were fully anesthetized with ketamine (100mg/kg) and acepromazine
(3mg/kg), and perfused through the heart with 20ml of PBS followed by 20 ml of 4%
paraformaldehyde (PFA) in PBS. The brains were post-fixed overnight in 4% PFA at 4oC
followed by incubation in 30% sucrose solution for 24 hours at 4oC for cryoprotection. The
brains were then frozen at -80oC until used. Coronal sections 30µm in thickness were cut in a
microtome at -20oC and collected serially from the striatum between bregma 0.14 and 1.54 mm.
About 50 coronal sections were collected from each animal and stored in anti-freezing solution
(30% glycerin solution in ethylene glycol) at -20oC until used. For intrastriatal surgeries, brain
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tissue was nicked in the left dorsal cortex for orientation.
3. Intrastriatal Infusion
The surgical technique for intrastriatal infusion was performed as previously described (Wang
and Angulo, 2011). In brief, animals were anesthetized by 2.5% isoflurane followed by shaving
on the skull. The skin was then disinfected by iodine on a sterile cotton swab. After fixing the
head in the stereotaxic instrument, a one-inch incision was made with a hand held razor blade
above the injection site. A hole of 1millimeter diameter was drilled in the skull and a 25 gage 2µl
Hamilton microinjection syringe was lowered into the striatum. The location of injection sites
(bregma, 0.5 mm; lateral, 2.0mm; ventral, 2.5mm) was determined using a mouse brain atlas
(Franklin and Paxinos, 1997). The needle was left in the position for five minutes before infusion
of 1ul PD149163 (20µM)/SR48692 (20µM) into the right striatum (bregma: 2.0mm, lateral:
0.5mm, ventral: 2.5mm) and aCSF into the left striatum (bregma: 2.0mm, lateral: 0.5mm,
ventral: 2.5mm). Thirty minutes after the intrastriatal infusion, 30 mg/kg METH were injected
intraperitoneally into the mice. Intrastriatal infusion of PD149163 will eliminate its function to
reduce the body temperature, making it possible to detect its role in METH-induced striatal
apoptosis independent of body temperature regulation. Intrastriatal infusion of SR48692 will
avoid the activation of neurotensin receptor 2 outside the striatum by SR48692,
4. Apoptosis detection: TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end
labeling) histochemistry
The method is adapted from X. Deng, 2001 with minor modifications. In brief, the 30µm tissue
coronal sections from each mouse were dissected and serially collected from the striatum
between bregma 0.14 and 1.54mm into six adjacent wells. Five sections were randomly selected
from one well of each of the adjacent wells and mounted on frog plus slides. The slides were
washed three times in PBS for 10 minutes followed by heating in 0.4% Triton X-100 PBS for 40
min at 70°C. TUNEL reagents were then applied to sections and incubated at 37°C for four
hours. The remaining reagents were then removed by cleansing with PBS and the slides were
covered with Vectashield mounting medium H1000 and No. 1.5 coverslips. All images were
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obtained from both hemispheres of each coronal section using a Leica SP2 Confocal microscope
with TRICT filter (Leica Microsystems; Buffalo Grove, IL).
5. Neuronal Nuclei (NeuN) immunohistochemistry
Coronal sections of the striatum were washed with PBS for 10 minutes and then incubated in
primary antibody of Anti-NeuN (rabbit polyclonal, 1:50, Millipore; Temecula, CA) for two
hours at room temperature. After PBS wash, all sections were incubated in 1:200 Donkey antiRabbit secondary antibody (Millipore; Temecula, CA) and then covered with Vectashield
mounting medium H1000. All images were obtained from both hemispheres of each coronal
section using a Leica SP2 Confocal microscope with Cy3 filter (Leica Microsystems; Buffalo
Grove, IL).
6. Cell counts and quantification
All coronal sections were taken from Bregma 0.14-1.54 mm. Cells were counted from 30µmthick coronal sections in an area of 0.26 mm2 for each region of the striatum (lateral and medial).
For the sections collected from the microinjected mice, regions around the needle track were
spared; the lateral and medial images were then counted. TUNEL and striatal neuronal cell
counts were averaged from five 30µm serial sections per animal.
7. Presynaptic neurodegeneration: Immunoblot of Tyrosine Hydroxylase (TH)
All groups of mice were decapitated under full anesthesia with 2.5% isoflurane 72h after i.p.
drug injection. All the brains were removed by dissection and kept in -80°C until further
operation. A coronal section of the striatum 2mm thick was removed by using a brain blocker on
ice and kept at -80°C for protein extraction. Each striatal homogenate in 200ul RIPA buffer was
obtained by sonication with a Sonicator 3000 (QSonica; Newtown, CT) cup horn at 6 cycles of
30-second sonication with 60 seconds intermittent on ice. Only the soluble supernatant was
collected after centrifuge at 5000rpm for 15 minutes as a protein sample for TH immunoblot.
Concentration of each protein sample was detected by the Bradford Method (Bio-Rad; Hercules,
CA) and 12µg protein of each sample was boiled for seven minutes at 95°C with a proteinloading buffer (Bio-Rad; Hercules, CA). 10% Tris-HCL SDS-PAGE gel (Bio-Rad; Hercules,
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CA) was used to separate proteins only according to protein molecular weight. After transferring
proteins to the PDVF membrane with iBlot transfer system (Invitrogen; Carlsbad, CA), the
membrane was blocked with an Odyssey blocking buffer for one hour followed by incubation
with polyclonal rabbit anti-TH primary antibody (1:5,000, Millipore; Temecula, CA) and
monoclonal mouse anti β-actin primary antibody (1:20,000, Sigma; St. Louis, MO) in an
Odyssey blocking buffer with 0.2% Tween 20 at 4 degrees overnight. The following day, after
0.1% Tween PBS wash, the membrane was incubated in a mixture of Odyssey IRDye secondary
antibodies: donkey anti-rabbit 800CW (1:15,000, Licor; Lincoln, NE) and donkey anti-mouse
680LT (1:22500, Licor; Lincoln, NE) in an Odyssey blocking buffer with 0.2% Tween 20 at
room temperature for one hour. After four final washes with 0.1% Tween PBS, the membranes
were detected via the Odyssey infrared imager. Bands were quantified by Odyssey Imager
analysis software and normalized against actin as internal standards.

8. Quantitative Real Time PCR (qRT-PCR) for Neurotensin and GAPDH in the striatum
Two groups of mice (each contains 6 animals) were decapitated under full anesthesia with 2.5%
isoflurane. Brains were dissected and stored at -80°C for further treatment. The striatum was
dissected and manually homogenized on ice, and RNA was extracted using RNeasy Mini kit
(Qiagen; Valencia, CA). The RNA concentration levels were measured by Nanodrop 1000
(Thermo scientific; Waltham, MA). RNA template of 0.5ng, 5ng, 10ng and 25ng was applied to
run the validation experiments for Comparative Ct method. And 10ng of RNA was chosen as the
template for the following qRT-PCR. TaqMan Gene Expression Assay of Neurotensin (FAM
probe, Life Technologies; Carlsbad, CA) and TaqMan Rodent GAPDH control reagent (VIC
probe, Life Technologies; Carlsbad, CA) were used as primers in each qRT-PCR system with
TaqMan RNA-to-Ct 1 step kit. Applied BioSystems 7500 Real-Time PCR System was used to
operate the following cycles: 48°C for 15 minutes; 95°C for 10 minutes; followed by 40 cycles
of 95°C for 15 seconds and 60°C for 1min. All Ct values were detected by 7500 Real-Time PCR
System automatically and used for further statistical analysis by the Comparative Ct method.
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9. Core body temperature detection
Core body temperature was determined using a BAT-12 thermometer coupled to RET-3 mouse
rectal probe (Physitemp Instruments; Clifton, NJ). Individual mouse body temperatures were
measured twice to obtain the average. Ambient room temperature was maintained at 20-22°C
during the measurement period.
10. Astrocyte cell activation: GFAP immunohistochemistry
Three days after i.p. drug injection of four groups, mice were perfused and dissected as described
above. Tissue sections of 30µm were then stored at -20°C until use. Five sections were randomly
selected from one well of each six adjacent wells. Coronal sections were then washed with PBS
and incubated in anti-GFAP primary antibody (rabbit polyclonal, 1:25, Millipore; Temecula,
CA) for two hours at room temperature. After washing with PBS, the sections were mounted
with Vectashield mounting medium H1000 and No. 1.5 coverslips. All images were obtained
from both hemispheres of each coronal section using Leica SP2 Confocal microscope with
TRICT filter (Leica Microsystems; Buffalo Grove, IL).
11. Microglial cell activation: Iba-1 immunohistochemistry
Coronal sections of the striatum were obtained as described in GFAP immunohistochemistry. All
sections were then washed with PBS followed by blocking in 5% Donkey serum for 30 minutes.
After blocking, all sections were incubated in anti Iba-1 primary antibody (rabbit polyclonal,
1:500, Millipore; Temecula, CA) overnight at 4°C. After PBS wash, the sections were incubated
in 1:200 Donkey anti-rabbit secondary antibody (Millipore; Temecula, CA) and then covered
with Vectashield mounting medium H1000. All images were obtained from both hemispheres of
each coronal section using Leica SP2 Confocal microscope with TRICT filter.
12. Nitric oxide accumulation: cyclic GMP immunohistochemistry
Eight hours after i.p. injection of METH and NTR1 agonist, animals were perfused and coronal
sections of the striatum were obtained as described in GFAP immunohistochemistry. All sections
were washed with PBS and then blocked in 10% Donkey serum (Sigma; St. Louis, MO) in 0.1%
24

Tx-PBS for 30 minutes. After three PBS washes, the sections were incubated in anti-cGMP
primary antibody (rabbit polyclonal, 1:200, Millipore; Temecula, CA) for 18 hours at 4°C. After
another PBS wash, all sections were incubated in 1:200 Donkey anti-rabbit secondary antibody
(Millipore; Temecula, CA) in 1% donkey serum (Sigma; St. Louis, MO) and then mounted. All
dry sections were then covered with Vectashield mounting medium H1000 and No. 1.5
coverslips. Leica SP2 Confocal microscope with TRICT filter was used to obtain all images from
both striata of each coronal section.
13. Immunoblot of DARPP32 and phosphorylated DARPP32 at Thr34 (p34 DARPP32)
To analyze the DARPP32 and p34 DARPP32 protein levels affected by the NTR1 agonist,
PD149163 was i.p. injected into mice 30 minutes before METH administration. For analysis of
protein levels in NTR1 antagonist experiment, SR49682 was infused into the striatum through
stereotactic injection followed by METH administration 30 minutes later. One hour after METH
injection, all animals were decapitated and a section of the striatum 2 mm thick was immediately
dissected on ice. Each coronal section of the striatum was placed in 200µl RIPA buffer (Sigm;
St. Louis, MO) with protease inhibitor cocktail (1:100, Sigma; St. Louis, MO), phosphatase
inhibitor cocktail 2 (1:100, Sigma; St. Louis, MO) and phosphatase inhibitor cocktail 3
(1ml/500mg tissue, Sigma; St. Louis, MO). The striatum tissues were then subjected to
sonication for six cycles of 30 seconds at one-minute intervals and centrifugation at 5000 rpm for
15 minutes to obtain the supernatant. Protein concentration of the supernatant was detected
through the Bio-Rad protein assay. 35µg of protein was boiled for seven minutes with loading
buffer followed by electrophoresis in 4-20% Tris-HCL SDS-PAGE gel (Bio-Rad; Hercules, CA).
After transferring proteins to the PDVF membrane using the iBlot transfer system (Invitrogen;
Carlsbad, CA), the membrane was blocked with an Odyssey blocking buffer for one hour at
room temperature. Polyclonal rabbit anti-DARPP32 primary antibody (1:5,000, Millipore;
Temecula, CA), or polyclonal rabbit anti-p34 DARPP32 primary antibody (1:1,000, Millipore;
Temecula, CA) with monoclonal mouse anti β-actin primary antibody (1:20,000, Sigma, St.
Louis, MO) were applied to the membrane in 10ml 0.2% Tween 20 Odyssey blocking buffer at 4
degrees overnight. After 0.1% Tween PBS wash, the membrane was incubated in a mixture of
Odyssey IRDye secondary antibodies: donkey anti-rabbit 800CW(1:10,000, Licor; Lincoln, NE)
and donkey anti-mouse 680LT(1:20,000, Licor; Lincoln, NE), in 15ml Odyssey blocking buffer
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with 0.2% Tween 20 at room temperature for one hour. After final washes with 0.1% Tween
PBS, the membranes were detected via Odyssey infrared imager (Licor; Lincoln, NE). Bands
were quantified by Odyssey Imager analysis software and normalized against β-actin as internal
standards.
14. Statistical analysis
Analysis was performed from Means±SEM. Differences between two groups (Group 1 and
Group 2 in Table 1) were analyzed by student t-test. Differences between four groups (As
described in Table 1) were analyzed by one-way analysis of variance (ANOVA), followed by
Tukey comparison. The p-value was set as 0.05. The null-hypothesis, indicating no significant
difference between groups, was rejected when the p-value was less than 0.05.

Table 1. Treatment of four groups of mice
Group 1

Group 2

Injection 1

PBS

PBS

Injection 2

PBS

METH

Group 3

Group 4

PD149163/SR48692 PD149163/SR48692
METH

PBS
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CHAPTER 3. RESULTS
1. The Neurotensin receptor 1 agonist (PD149163) attenuates METH-induced striatal
apoptosis in a dose-dependent manner
To determine its effect on METH-induced striatal apoptosis, we delivered PD149163, the NTR1
agonist, through i.p. injection to facilitate its penetration of the brain blood barrier. Since it has
been shown that i.p. injection of 1mg/kg and 2mg/kg of PD149163 exerts effects on NTR1 in
mice (Feifel et al., 2004; Shilling et al., 2004), we used dosages of 0.5 mg/kg, 1 mg/kg and 2
mg/kg to examined the effects of NTR1 agonist on METH-induced striatal apoptosis and
determine the optimal dosage.

Since METH-induced striatal apoptosis is limited to the striatal neurons (Zhu et al., 2006), we
assessed the apoptotic ratio of striatal neurons by calculating the ratio of apoptotic cells to the
number of total striatal neurons. To that end, we labeled the striatal apoptotic cells and striatal
neurons by TUNEL and NeuN respectively. Terminal deoxynucleotidyl Transferase dUTP Nick
End Labeling (TUNEL) can illustrate DNA fragmentation within cells, a late-stage hallmark of
apoptosis in situ (Nagata, 2000). The DNA fragments inside the nucleus were labeled by
Fluorescein (FITC) and emitted green fluorescence after excitement as shown in Figure 3. We
also labeled striatal neurons with NeuN, a neuron nuclear biomarker, with red fluorescence
(Cy3) through immunohistochemistry. We used confocal microscopy to obtain images of the
striatum in four quarters (Ventral Medial, Ventral Lateral, Dorsal Medial, and Dorsal Lateral)
and counted the apoptotic cells and total neurons in the striatum using Image J software. Data
analysis indicated METH-induced TUNEL staining in 15.24±7% of striatal neurons compared
27

with 0.31% TUNEL positive neurons in the striatum of the control animals. The observation that
METH induced significant apoptosis in the striatum is consistent with our laboratory's previous
findings (Xu et al., 2005; Zhu et al., 2005). The NTR1 agonist, PD149163, affects METHinduced striatal apoptosis in a dose-dependent manner ranging from 0.5 mg/kg to 2 mg/kg. All
three dosages of PD149163 affected the ratio of apoptotic neurons in the striatum, with 1mg/kg
and 2mg/kg attenuating apoptosis significantly. In particular, pre-treatment of the PD149163 at 1
mg/kg and 2 mg/kg (i.p.) attenuated 86.2% and 96.7% of METH-induced striatal neuron
apoptosis respectively. Due to its strongest protective effect of PD149163 at 2 mg/kg, we
identified 2mg/kg as the optimal dosage and thus used 2mg/kg in all subsequent experiments.
PD149163 treatment alone does not affect the apoptotic levels compared with control mice as
shown Figure 3. Our findings also indicated that, as predicted, the neuropeptide neurotensin
contributes to METH-induced striatal neuron apoptosis, and its agonist, PD149163, could
become a potent drug candidate for treatment of METH-induced neurotoxicity.
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Figure 3. NTR1 agonist attenuates METH-induced striatal neuron apoptosis. NTR1 agonist was
i.p. injected into mice at 0.5mg/kg, 1mg/kg and 2mg/kg 30min before METH i.p. injection. (A)
Scanning confocal micrographs of TUNEL straining and NeuN staining in striatum of mice. Arrows
indicate TUNEL positive cell (green) and NeuN positive cell (red). (B) Percentage of striatal neurons
displaying TUNEL staining. Data represent Means±SEM; all data were analyzed by one-way ANOVA
followed by Tukey. ∗ p≤0.05 compared with PBS control; !p≤0.05, !!p≤0.01 compared with METH 29
group.
n≥6. Scale bar=75µm.

2. NTR1 agonist exerts no effect on METH-induced dopamine terminal degeneration
In addition to striatal neuron apoptosis, METH can also induce dopamine terminal degeneration
characterized by depletion of dopamine, tyrosine hydroxylase, and dopamine transporter (Wilson
et al., 1996). We assessed the level of tyrosine hydroxylase (TH), a dopamine terminal
degeneration biomarker. TH is an enzyme that catalyzes the rate-limiting step of dopamine
synthesis in the dopamine terminals. We quantified the TH levels in striatal homogenates by
western blot with β-actin as the internal control for its constant expression in cells. Since METH
has been shown to induce the lowest depletion of TH at 72 hours (Zhu et al., 2005), we used this
as our time point and showed that METH reduced TH levels by 42% 72 hours after systemic
administration. Systemic delivery of PD149163 thirty minutes prior to METH administration did
not significantly affect the TH level, with an increase of 16% (Figure 4). Additionally,
PD149163 alone did not alter TH levels significantly. These results suggest that, even at optimal
dosage, PD149163 has no effect on METH-induced dopamine terminal degeneration.
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Figure 4. Pretreatment of PD149163 has no effect on METH-induced tyrosine hydroxylase
depletion. Mice in all four groups received all drugs through i.p. injection. 2mg/kg PD149163 was
injected 30min before METH. (A) Scanning western blot image of TH and β-actin bands by Odyssey
imager. (B) Corresponding level of tyrosine hydroxylase in striatum of four mice groups. Data
represents Means±SEM; all data were analyzed by one-way ANOVA followed by Tukey. ∗p≤0.05,
∗∗∗
p≤0.001 compared to PBS control group. n≥6. Note that no significant difference in tyrosine
hydroxylase level was found between the METH group and the PD149163 pre-treated METH group.
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3. METH up-regulates neurotensin gene expression in the striatum
Systemic delivery of the NTR1 agonist attenuating apoptosis of striatal neurons indicates that
neurotensin may respond to METH administration by activating the NTR1. We hypothesized
that METH administration would decrease the intracellular neurotensin peptide pool and thereby
increase the preproneurotensin mRNA levels to restore the peptide pool.

To test this hypothesis, we delivered either METH (30 mg/kg) or PBS (phosphate buffered saline)
as control through i.p. injection and measured the neurotensin mRNA level in the striatum six
hours post administration in these two groups using quantitative Real-Time PCR. We chose six
hours as the time point since Letter (Letter et al., 1987) showed that a single dose (15 mg/kg) of
METH elevated neurotensin-like imunoactivity concentration starting from six to eighteen hours.
The Taqman RT-PCR system (Life Technologies; Carlsbad, CA) was used to detect neurotensin
mRNA levels in mouse striata. GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) was used
as an endogenous control due to its ubiquitous and stable expression. The comparative Ct
method was chosen to interpret Ct values and qualified by verification experiments. 0.5ng, 5ng,
10ng and 25ng of total RNA from striata were extracted using RNeasy Kit (Qiagen; Venlo,
Limburg) and used as RNA template for this validation experiments. Each reaction was repeated
three times. After plotting the log of RNA concentration and the corresponding Ct values, we
observed the slopes of standard curves for neurotensin and GAPDH only differed by 0.03(Figure
5). The efficiencies of these two RT-PCR systems are similar enough (˂0.1) to be interpreted by
comparative Ct method (Schmittgen and Livak, 2008). The comparative Ct method then was
used to interpret all Ct values for neurotensin and GAPDH RT-PCR system and showed that the
neurotensin mRNA level reached up to 195±30% six hours after METH administration
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compared to the control as shown in Figure 6.

This result suggests that METH induces

neurotensin release from the striatal neurons and thereby triggers the up regulation of
neurotensin gene expression as characterized by elevated neurotensin mRNA levels. These data
also support our hypothesis that neurotensin responds to METH-induced pathology through
activation of NTR1 in the striatum.
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Figure 5. Validation of comparative Ct method for neurotensin and GAPDH RT-PCR
system. Input total RNA amount ranged from 0.5ng to 25ng as shown above for each RT-PCR
system. The absolute difference of these two slopes of the standard curves is 0.03 < 0.1, which
indicates that the efficiencies of these two RT-PCR systems are similar and the comparative Ct
method is applicable.
34

*

200

100

M

ET

H

S

0

PB

Relative Neurotensin gene expression
(% of control)

RT-qPCR

300

Figure 6. METH up regulates neurotensin gene expression at six hours post administration. Animals
received i.p. injection of either saline or METH (30mg/kg) and the total RNA from the striatum were extracted
and used as RNA template for real-time quantitative PCR. Ct value was interpreted by comparative Ct method
with Rodent GAPDH as internal control. Data were analyzed by student t-test. *p≤0.05 compared with PBS
control animals. n≥6.
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4. NTR1 agonist attenuates METH-induced hyperthermia
It has been shown that METH-induced hyperthermia plays a significant role in neurotoxicity
(Sandoval et al., 2000; Bowyer et al., 1994); indeed, environmental suppression of hyperthermia
attenuates METH-induced striatal neurodegeneration (Bowyer et al., 1992; Bowyer et al., 1993).
Several phenomena have been observed as consequences of hyperthermia, including
cerebrovascular damage, increased calcium entry, and oxidative stress (Davidson et al., 2001;
Lin et al., 1991; Omar et al., 1987; Skibba et al., 1991), all of which may induce neurotoxicity.
Due to the role of hyperthermia in METH-induced neurodegeneration, it has become necessary
to consider body temperature response when studying the mechanisms of METH toxicity. We
measured the core body temperature of animals using a rodent probe at four time points: 0 hours,
two hours, four hours, and six hours post drug administration. It has been shown that METHinduced hyperthermia vanished at six hours post injection of acute METH (30 mg/kg) (Zhu et al.,
2006). In this study, we observed an increase in body temperature from 37.5 °C to 39.6 °C at two
hours post METH; this increase is temporary, as temperature drops to 36.5 °C at four hours
(Figure 7). Systemic delivery of the NTR1 agonist attenuated hyperthermia and maintained core
body temperature at 37 °C at two hours, followed by a decrease to 34.1°C at four hours post
METH administration. The hypothermic effect of PD149163 was also observed in the PD149163
treatment only group; these mice displayed a sharp reduction of body temperature by 5.1°C
(from 38.3 °C to 33.2 °C) at two hours post administration. These data suggest that systemic
delivery of PD14963, the NTR1 agonist, attenuates METH-induced hyperthermia in mice at two
hours post administration.
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Figure 7. Systemic delivery of PD149163 attenuates METH-induced hyperthermia. All
drugs were i.p. injected into mice of four groups. Core body temperatures were detected by
thermometer probe for rodents at four time points post injection. Data represent Means±SEM;
all data were analyzed by one-way ANOVA followed by Tukey. ∗p≤0.05, ∗∗p≤0.01,
∗∗∗∗
p≤0.0001 compared with PBS control, !p≤0.05, !!!! p≤0.0001 compared with METH group.
n≥6. Arrows indicate at 2 h post i.p. injection, METH induces body temperature increase
while PD149163 causes reduction of body temperature.
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5. NTR1 agonist attenuates striatal neuron apoptosis independent of body temperature
regulation
To investigate whether NTR1 agonist can attenuate striatal apoptosis independent of body
temperature regulation, we sought to bypass its hypothermic effect by stereotactic injection
oPD149163 into the striatum. We microinjected 1 µL aCSF asvehicle into the left striatum and
20 µM PD149163 of 1 µL into the right striatum (stereotactic coordinates: 0.5 mm anterior, 2.0
mm lateral from bregma and 2.5 mm ventral). Thirty minutes post microinjection, mice received
i.p. injection of METH or PBS, and then the core body temperatures were monitored at 0 hours
and two hours post i.p. injection. PD149163 infused in the striatum exerted no effect on body
temperature regulation, as evidenced by a 2.0 °C increase in core body temperature at two hours
post PD149163 intrastriatal infusion and METH i.p. injection, as shown in Figure 8. The TUNEL
staining shows METH-induced striatal apoptosis with large intra-animal variance; half of the
METH-treated mice (n=4) showed a high degree of apoptosis while the other four mice showed a
low degree of apoptosis. These findings, shown in Figure 9, are consistent with previous findings
illustrated in Figure 3 and also shown by Zhu et al. (2006). Notably, while confocal micrographs
showed 37.7% of the striatal neurons undergoing apoptosis after aCSF infusion and METH i.p.
injection, the right striatum infused with PD149163 followed by METH i.p. injection showed
only an average of 3.6% apoptosis (Figure 9A). As a comparison, less than 2% of striatal
neurons experienced apoptosis in animals treated with aCSF or PD149163 infusion followed by
PBS i.p. injection, which indicates that aCSF and PD149163 exert no effect on striatal apoptosis.
These observations demonstrate that the NTR1 agonist, PD149163, can attenuate striatal
apoptosis independent of its regulation of body temperature.
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Figure 8. Intrastriatal infusion of PD149163 has no effect on METH-inducecd
hyperthermia. Mice received 20 µM PD149163 in the right striatum (Coordinate: bregma
0.5mm; lateral 2.0; ventral 2.5mm) and vehicle aCSF in the left striatum (Coordinate: bregma
0.5mm; lateral 2.0; ventral 2.5mm) through stereotactic infusion. Followed by infusion, i.p.
injection of 30 mg/kg METH was given to the mice 30 min post the PD 149163 infusion. Core
body temperatures were detected 0 h and 2 h after the METH injection. All temperatures were
detected twice. Data represent Means±SEM and were analyzed by student t-test. ∗∗p≤0.01
compared with core body temperature at 0 h post i.p. injection of METH. n=8.
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Figure 9. Intrastriatal microinjection of NTR1 agonist attenuates METH-induced striatal
apoptosis. Mice received 20uM PD149163 infusion in right striatum (Coordinate: bregma 0.5mm;
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Scanning confocal micrographs of TUNEL staining. Scale bar= 715.48 µm. (B) Percentage of
striatal neurons displaying TUNEL staining. Data represent Means±SEM; all data were analyzed
by one-way ANOVA followed by Tukey. ****p≤0.0001 compared with aCSF infusion &Saline i.p.
Control group,!!!p ≤0.001 compared with aCSF infusion &METH i.p. Group.
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6. NTR1 agonist attenuates activation of glial cells induced by METH in the striatum

The innate immune cells of the central nervous system, glial cells, are composed of microglia
and astrocytes primarily in the brain (Sofroniew and Vinters, 2010; Stollg and Jander, 1999).
Glial cells have been acknowledged to play a role in METH-induced neurotoxicity as evidenced
by the fact that activations of both microglia and astrocytes are found in METH-treated rodents
and METH abusers (Zhu et al., 2005; Sekine et al., 2008). Once reactivated, glial cells can
produce several proinflammatory factors that are toxic to neurons such as IL-1, TNF-α and NO
(Dinarello, 2000; Hanisch, 2002; Mark and Grinffin, 2005). These proinflammatory factors may
drive neurodegenerative diseases by inducing cellular damage and even apoptosis (Liu and
Hong, 2003; LaVoie et al., 2004; Wyss-Coray, 2006). To measure the effect of the NTR1
agonist, PD149163, on glial cell activation induced by METH, microglia were labeled with its
biomarker, ionized calcium-binding adapter molecule 1 (Iba-1) (Imai et al., 1996), and astrocytes
with glial fibrillary acidic protein (GFAP) (Eng et al., 2000; Bignami et al., 1972), through
immunohistochemistry since activation of microglia and astrocytes lead to over-expression of
Iba-1 and GFAP, respectively. Confocal microscopy was used to show the Iba-1 and GFAP
staining in coronal sections of striatal tissues. Iba-1 staining showed that METH led to enlarged
cell body and highlighted processes of microglia in addition to intense staining of Iba-1, which
characterized the activation of microglia. In particular, METH induced microglia to form a
hypertrophic, reactive shape as opposed to their resting, ramified shape. Also, the level of Iba-1
reached up to 185.3% of PBS control after METH treatment (Figure 10). Co-administration of
PD149163 and METH attenuated such activation characterized by a resting ramified shape of the
microglia and low levels of Iba-1, (86.97% of PBS control) (Figure 10). PD149163 treatment
alone showed no effect on Iba-1 levels or microglial morphology as compared to PBS control.
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Both morphology and Iba-1 levels indicate that the NTR1 agonist attenuated METH-induced
microglial cell activation in the striatum.

GFAP immunohistochemistry showed METH treatment induced more GFAP staining in the
astrocytes of the striatum as compared to PBS control. Due to the over expression of GFAP in
the astrocytes, we observed approximately 11.3 times more astrocytes present in the striatum
compared to the PBS control (Figure 11). PD149163 pretreatment attenuated such accumulation
of astrocytes by 78% as shown in Figure 11. Again, PD149163 treatment alone had no effect on
astrocyte activation as compared to the PBS control. This observation demonstrates that NTR1
agonist also attenuated activation of METH-induced astrocytes in the striatum.
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Figure 10. NTR1 agonist attenuates METH-induced glial cell activation. (A) Scanning
confocal micrographs of Iba-1 staining in the striatum. Scale bar=357.74 µm. Arrows indicate
individual microglia. (B) Level of Iba-1 and GFAP in striatum. Data represent Means±SEM; all
data were analyzed by one-way ANOVA followed by Tukey. **p≤0.01,***p≤0.001 compared
with PBS control; !!p≤0.01, !!!p≤0.001 compared with METH group.
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7. NTR1 agonist attenuates nitric oxide accumulation induced by METH in the striatum
The tiny molecule nitric oxide (NO), a reactive gas, can function both as a neurotransmitter and a
killer molecule by activating the immune system in the brain (Änggård, 1994). Our laboratory
has found that acute METH can induce over production of NO up to 32 hours post administration
(Zhu et al., 2009) and pharmacological inhibition of nNOS (neuronal nitric oxide synthase) by 7nitroindazole could attenuate METH-induced striatal neurotoxicity (Itzhak and Ali, 1996; Zhu et
al., 2009). As a reactive free radical, Nitric Oxide has a short half-life and therefore is difficult to
detect in situ (Nagano et al., 1999). Nevertheless, it is possible to quantify the byproducts of NO,
such as cyclic guanosine monophosphate (cGMP) as its biomarker. The levels of cGMP in the
striatum were assessed in situ using immunohistochemistry. The confocal micrographs of cGMP
staining showed that METH (30mg/kg, i.p.) induced 157% levels of cGMP as compared to PBS
control in the striatum (Figure 12). PD149163 pretreatment attenuated 70% of such accumulation
(110% of the control) and PD149163 alone had no effect on cGMP levels as compared to the
control. These data suggest that the NTR1 agonist significantly affects METH-induced NO
accumulation. Furthermore, our lab has found that cGMP levels become elevated in all types of
neurons in the striatum, including projection neurons and interneurons along with NO
accumulation induced by METH in the striatum (Yarosh and Angulo, 2012). Based on this
finding, the NTR1 agonist may attenuate METH-induced increase in cGMP levels in the striatal
projection neurons as well as the striatal interneurons.
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Figure 12. NTR1 agonist attenuates METH-induced cyclic GMP accumulation in the
striatum. (A). Scanning confocal micrographs of cGMP staining in the striatum. (B).
Quantification of cGMP level in the striatum. Data represent Means±SEM. All data were
analyzed by one-way ANOVA followed by Tukey. ∗∗ p≤0.01 compared to PBS group; !p≤0.05,
!!
p≤0.01 compared to METH group.
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8. NTR1 modulates METH-induced phosphorylation of DARPP32 at Thr34 in the striatum

In the striatum, DARPP32 is highly concentrated in the medium-sized projection neurons and is
found to play a central role in interpreting all neurotransmissions into the projection neurons
(Greengard, 2001). The fact that DARPP32 knock-out mice showed little or no response to
psychostimulant drugs at biochemical, behavioral and physiological levels indicates the role of
DARPP32 in modulating such processes. DARPP32 exerts its effects through phosphorylation or
dephosphorylation by multiple pathways including dopamine and glutamate neurotransmission.
To investigate the effect of NTR1 on phosphorylation of DARPP32 at Thr34, DARPP32 and
phosphor-Thr34 DARPP32 levels were measured in mice striata using western blot. The NTR1
agonist was delivered intraperitoneally followed by METH i.p. injection. We also delivered PBS
followed by PBS i.p. injection as the control group. The time point for the highest amount of
phosphorylation of DARPP32 at Thr34 induced by METH was selected at one-hour post METH
injection. At six and eight hours post METH, levels of DARPP32 and phosphor-Thr34
DARPP32 were not affected compared to the control animals (Figure 13), which is consistent
with previous findings (P-C Chen and J-C Chen, 2005). At one hour post administration,
however, METH induced phosphorylation of DARPP32 at Thr-34 up to 140% of the control,
while pretreatment of PD149163 attenuated such phosphorylation of DARPP32 to 51% of
control (Figure 14). In contrast, the levels of total DARPP32 in the striatum were unaffected by
any drug administration. Additionally, the NTR1 agonist alone also decreased levels of
phosphorylation of DARPP32 at Thr34 by 54% compared to the control group. This suggests
that PD149163 attenuates METH-induced DARPP32 phosphorylation in the striatum at one-hour
post administration.
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To further investigate the function of NTR1 on METH-induced DARPP32 phosphorylation, the
effect of the NTR1 antagonist, SR48692, on levels of phorsphorylated DARPP32 at Thr34 and
DARPP32 were assessed one hour after METH i.p. injection following intrastriatal infusion of
the NTR1 antagonist. The NTR1 antagonist was delivered through intrastriatal infusion to
eliminate its function to activate NTR2 outside the striatum. Western blot data indicated that
METH induced 224% of p34 DARPP32 compared to the control animals and the NTR1
antagonist augmented such phosphorylation of DARPP32 by 146% (370% of control animals)
(Figure 15). It is also notable that SR48692 alone also promoted the phosphorylation of
DARPP32 at Thr34 by 122% compared to the control group. The contrasting effects of NTR1
agonist and antagonist on METH-induced DARPP32 phosphorylation demonstrate that through
regulating neurotransmission, NTR1 modulates phosphorylation of DARPP32 at Thr34.
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Figure 13. METH does not affect levels of both DARPP32 and p34 DARPP32 in striatum
6h/8 h post drug. (A). Western blots of DARPP32, phosphor Thr34 DARPP32, and β-actin in
striatum at six and eight hours post METH administration. (B) Quantification of DARPP32 and
phosphor Thr34 DARPP32 in striatum with β-actin as internal control. Data represent
Mean±SEM; all data are analyzed by one-way ANOVA followed by Tukey. n≥6.
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Figure 14. NTR1 agonist attenuates METH-induced phosphorylation of DARPP32 at Thr
34 in striatum at one-hour post METH. (A). Western blots of DARPP32, phosphor Thr34
DARPP32, and β-actin in the striatum. (B) Quantification of DARPP32 and phosphor Thr34
DARPP32 in striatum with β-actin as internal control. Data represent Mean±SEM; all data are
analyzed by one-way ANOVA followed by Tukey. n≥6. *p≤0.05, **p≤0.01 compared with PBS
control animals, !!!!p≤0.0001 compared with METH-treated animals.
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Figure 15. NTR1 antagonist augments METH-induced phosphorylation of DARPP32 at
Thr 34 in the striatum at one-hour post METH. (A) Western blots of DARPP32, phosphor
Thr34 DARPP32, and β-actin in the striatum. (B) Quantification of DARPP32 and phosphor
Thr34 DARPP32 in striatum with β-actin as internal control. Data represent Mean±SEM; all
data are analyzed by one-way ANOVA followed by Tukey. n≥6. *p≤0.05, **p≤0.01 compared
with aCSF & saline treated animals, !p≤0.05, !!p≤0.01 compared with SR48692 and METHtreated animals.
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CHAPTER 4. DISCUSSION
METH has been shown to induce neural degeneration in several regions of the brain, including
the striatum, in rodents (Green et al., 1992; Jason-Davis et al., 2003; Ladenheim et al., 2000).
The toxicity of METH is thought to depend on its similar chemical structure to dopamine (DA)
(Iversen, 2006). Due to this structural similarity, METH can enter dopamine terminals readily via
DA transporters (Iversen, 2006), causing a premature release of DA inside the cytoplasm. The
DA then rapidly auto-oxidizes, forming reactive oxygen species such as superoxide radicals,
hydroxyl radicals, hydrogen peroxide and DA quinones (Acikgoz et al., 1998; Cubells et al.,
1994; Kita et al., 1999; Larsen et al., 2002; LaVoie and Hastings, 1999). These reactive oxygen
species may oxidize multiple cell components such as protein, lipid and nucleic acids, thus
impairing their functions through oxidative stress (Coyle and Puttfarchen, 1993; Buttke and
Sandstrom, 1994). In addition, METH reverses the function of DA transporters shuttling DA into
synapses, resulting in heavy DA overflow between dopamine terminals and post-synaptic
neurons in the striatum (O'Dell et al., 1993; Weihmuller et al., 1992). DA overflow induces
neuron hyperactivity and neurotoxicity to post-synaptic neurons, mainly in striatal medium sized
spiny projection neurons (MSNs), as DA projection from the midbrain to the striatum accounts
for the bulk of DA innervation in the CNS. Because of the critical role of DA in METH-induced
neurodegeneration, many studies have focused on this neurotransmitter. However, there are
currently no therapeutic options available for treatment of METH-induced neurotoxicity. It is
therefore essential to study the systems that regulate DA neurotransmission. Neurotensin is a
tridecapeptide heterogeneously distributed in the central nervous system (CNS) and the
gastrointestinal tract of mammals (Nemeroff et al., 1980). In the striatum, neurotensin is known
to modulate both dopamine and glutamate neurotransmission via interactions with NTR1,
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Dopamine receptor 1 and NMDA receptors (Dobner, 2005). Systemic delivery of neurotensin or
a neurotensin analog antagonizes certain METH-induced behaviors (Hertel et al., 2001; Hanson
et al., 2012), which supports the hypothesis that neurotensin participate in METH-induced
pathology by interacting with the DA system in the CNS. Furthermore, psychostimulants such as
methamphetamine and amphetamine have been shown to increase extracellular levels of striatal
neurotensin (Wagstaff et al., 1996; Ervin et al., 1982; Robledo et al., 1993), which further
suggests a role for neurotensin in psychostimulant-induced striatal neuronal activation. However,
to date, no information is available on the neurochemical effect of neurotensin in METH-induced
striatal neurodegeneration, let alone its corresponding mechanisms.

Our lab has been investigating the mechanisms of striatal neurodegeneration induced by acute
METH in a mouse model. In this model, we utilize the ability of METH (30mg/kg, i.p.) to induce
neurodegeneration in both presynaptic dopamine terminal and postsynaptic neurons in the striata
of mice (Xu et al., 2005; Zhu et al., 2006). In particular, dopamine terminals from presynaptic
neurons were shown to undergo neurodegeneration characterized by depletion of dopamine,
tyrosine hydroxylase, and dopamine transporters (Wilson et al., 1996). Meanwhile, 20% of
postsynaptic neurons, i.e., striatal medium-sized spiny neurons, were shown to experience
apoptosis as a result of acute METH exposure.

Using this animal model, the present study shows that the striatal endogenous neuropeptide,
neurotensin, modulates METH-induced striatal neuron apoptosis through neurotensin receptor 1.
In particular, systemic delivery of an NTR1 agonist, PD149163, was shown to attenuate METHinduced striatal apoptosis in a dose-dependent manner ranging from 0.5mg/kg to 2mg/kg.
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Among these dosages, 2 mg/kg is the optimal dose since at this dose, PD149163 attenuated the
striatal apoptosis by 96.7%. This result suggests that NTR1 plays an important role in METHinduced striatal apopotosis and reveal the potential of PD149163 as a treatment for METHinduced neurotoxicity and damage.

In addition to striatal apoptosis, acute METH also triggers neurodegeneration in presynaptic
neurons, e.g., dopamine neurons from SNc with tyrosine hydroxylase as a biomarker (Steiner
and Tseng, 2010; Wilson et al., 1996). We applied western blot to quantify the tyrosine
hydroxylase (TH) levels in the striatum in four different groups of animals (n≥6). Consistent
with previous reports, METH induced approximately 50% depletion of TH compared to the
control animals. Systemic delivery of NTR1 agonist at the optimal dosage of 2mg/kg did not
significantly affect such depletion. These data imply that despite modulating METH-induced
apoptosis, NTR1 does not participate in METH-induced dopamine terminal degeneration. And
the reason may lie on the fact that although neurotensin receptor 1 has been found in
dopaminergic terminals from the SNc (Quirion et al., 1985), no physiological interaction has
been found between NTR1 and DA transporters that are responsible for the subsequent
neurodegeneration by transporting METH into the dopamine terminal (Iversen, 2006).

To confirm the involvement of neurotensin in METH-induced pathology, we also examined
neurotensin gene expression by quantifying neurotensin mRNA levels in the striatum. After
analyzing the data from RT-PCR with comparative Ct method, we observed METH increased
neurotensin mRNA level by 96% compared to the control. This set of data supports our
hypothesis that METH administration increases the consumption of neurotensin, which induce
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the neurotensin gene expression in order to recover the neurotensin protein pool in the striatum.
Ultimately, the protective effect of NTR1 agonist against striatal neuron apoptosis, in
conjunction with METH-induced up-regulation of neurotensin gene expression, suggests that
neurotensin plays an important role in METH-induced striatal apoptosis. The corresponding
mechanisms may involve several pathways discussed in details as follows.

In the last four decades, investigations of METH-induced neurodegeneration have led to the
discovery of distinct mechanisms mediating this process (Gibb and Kogan, 1979; Yamamoto and
Bankson, 2005; Albers and Sonsalla, 1995; Bowyer et al., 1994; Escubedo et al., 1998; Guilarte
et al., 2003; Cadet and Krasnova, 2007.). Following a review of the literature and our lab’s
previous work, we hypothesized that hyperthermia, NO overproduction, glial cell activation, and
the DARPP32 signaling pathway are involved in neurotensin modulating METH-induced
neurodegeneration.

METH-induced hyperthermia plays a significant role in METH-induced neurodegeneration. In
particular, systemic delivery of METH can increase core body temperature up to 40°C, which, in
turn, can cause death in rodents (Molkov et al, 2014). Mild hyperthermia has also been found to
contribute to METH-induced neurodegeneration (Albers and Sonsalla, 1995) as evidenced by the
fact that environmental cooling or pharmacological manipulation, which directly attenuates
hyperthermia, also abrogates the neural damage induced by METH in various brain regions such
as the striatum (Ali et al., 1996; Albers and Sonsalla, 1995). Neurotensin is also shown to reduce
body temperature through activation of neurotensin receptor 1 by many studies. For example,
central administration of neurotensin can produce a marked dose-related decrease in body
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temperature of mice and rats at an ambient temperature 25°C (Nemeroff et al., 1977). Further,
targeted inactivation of the neurotensin receptor 1 revealed its role in body temperature control
(Remaury et al., 2002). Thereby, we speculate that endogenous neuropeptide neurotensin
attenuates METH-induced hyperthermia by lowering core body temperature dramatically
through NTR1. In this study, we assessed the effect of the NTR1 agonist, PD149163 (2mg/kg,
i.p. injection), on METH-induced hyperthermia. Our results corroborate the previous report on
METH-induced hyperthermia (Xu et al., 2005), in which acute METH dosage induced an
average increase of 2 to 3 °C in core temperature. Furthermore, systemic delivery of PD149163
reduced body temperature sharply by 6 °C, similar to a 1977 report by Nemeroff and colleagues.
Correspondingly, pretreatment of PD149163 attenuated METH-induced hyperthermia to normal
body temperature at two hours post i.p. injection. These data indicate that systemic delivery of
NTR1 agonist attenuates METH-induced hyperthermia through its function of core body
temperature regulation in mice. Hyperthermia may cause neuron damage through multiple
pathways involving cerebrovascular damage, increasing oxidative stress and even glial cell
activation as summarized in the introduction. As a result, prevention of hyperthermia at least
partially protects neurons from neurodegeneration.

In addition to body temperature regulation, we suspect there are other pathways involved in
protection of the NTR1 agonist against METH-induced striatal apoptosis based on previous
findings. In particular, certain pharmacological and genetic manipulations, which do not
influence core body temperature, also prevent METH-induced toxicity. For example, interleukin6 knockout mice displayed METH-induced hyperthermia, yet were resistant to METH-induced
axonal degeneration of dopamine and 5-HT neurons, as well as cell death and microgliosis
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(Ladenheim et al., 2000). In addition, nNOS inhibitors attenuated METH-induced dopamine
terminal degeneration while exerted no effect on METH-induced hyperthermia (Itzhak et al.,
2000). To test this hypothesis, we eliminated the NTR1 agonist’s ability to lower body
temperature through intrastriatal infusion of the NTR1 agonist. This allowed delivery of the
agonist into the striatum but not the hypothalamus, which regulates body temperature, in the
diencephalon of the CNS (Hammel et al., 1963; Hammel and Pierce, 1968). Infusion of the
NTR1 agonist had no effect on body temperature two hours post METH i.p. injection (Figure 8).
While lacking the hypothermic effect, infusion of the NTR1 agonist still attenuated striatal
apoptosis induced by METH in the striatum by 90%. These results support our hypothesis that
NTR1 can modulate METH-induced striatal apoptosis independent of body temperature
regulation. Based on this result, we further hypothesize that NTR1 modulates METH-induced
striatal apoptosis through several factors that contribute to METH-induced neurodegeneration
including glial cell activation, nitric oxide accumulation and DARPP32 phosphorylation
pathway.

METH-induced glial cell activation is supported to contribute to neurodegeneration by a
considerable body of evidences. As innate immune cells in the CNS, glial cells have long been
overlooked as merely supportive elements in the nervous system (Haydon, 2001; Sofroniew and
Vinters, 2010). Recently, glial cells have drawn more attention, which resulted largely from the
finding that glia can integrate neuronal inputs and modulate synaptic activity (Haydon, 2001;
Sofroniew and Vinters, 2010). Microglia and astrocytes are found to be both activated by METH
in rodents or human METH abusers, as shown by confocal microscopy and PET imaging (Sekine
et al., 2008; Zhu et al., 2005). Our lab has also found that acute METH administration (30mg/kg,
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i.p.) triggers the activation of astrocytes in the striatum, with a measured increase in GFAP levels
starting one-day post administration and peaking at three days (Zhu et al., 2005). Additionally,
increasing evidence suggests the potential role of immune response as an early stage biomarker
that can be targeted pharmaceutically for treatment of neurodegenerative diseases. For example,
Watson and colleagues demonstrated that the onset of inflammation in the striatum precedes the
development of nigrostriatal dysfunction in Line 61 mice, a transgenic mouse model of
Parkinson’s disease (Watson et al., 2013). LaVoie and colleagues (2004) also observed that
microglial activation precedes dopamine terminal pathology in METH-induced neurotoxicity.
Gill and colleagues further observed that direct brain infusion of glial cell line-derived
neurotrophic factor increases striatal DA storage by 28%, which indicates the direct involvement
of glia in psychostimulant abuse (Gill et al., 2003). These investigations support the role of glial
cell activation on METH-induced neurodegeneration.

To assess the activation of glial cells in situ, we chose to label the glial cells by
immunohistochemistry of Iba-1 (ionized calcium-binding adapter molecule 1) and GFAP (glial
fibrillary acid protein) in the striatum. Expression of GFAP has long been a prototypical marker
for immunohistochemical identification of astrocytes (Bignami et al., 1972; Sofroniew and
Vinters, 2010). Iba-1, a calcium-binding protein specifically expressed in microglia, was also
labeled by immunohistochemistry (Imai et al., 1996; Ito et al., 1998; Ito et al., 1998). GFAP and
Iba-1 can also reveal the activation of astrocytes and microglia with increased level and
morphological changes. The present study showed that systemic delivery of METH induced glial
cell activation in figures 10 and 11, with characterization of more processes, swelled cell bodies
and higher levels of Iba-1 and GFAP staining in the striatum. Pretreatment of NTR1 agonist with
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METH administration attenuated such activation with lower levels of GFAP and Iba-1, similar to
those of the control animals. Although it appears the population of astrocytes and microglial cells
in the striata of control animals and NTR1 agonist pretreated mice is similar, this is unlikely
given that there are five times as many glial cells as neurons in the CNS. It is more probable that
the antibodies for GFAP and Iba-1 fell below the threshold for detection in these groups of mice.
These results of Iba-1 and GFAP immunohistochemistry suggest that the NTR-1 agonist
suppressed METH-induced glial cell activation in the striatum.

The NTR1 agonist may attenuate METH-induced glial cell activation through reducing METHinduced apoptosis in the striatum. There are various factors that can trigger the activation of glial
cells, such as reactive oxygen species, glutamate accumulation in the synapse, environmental
toxins and infections, and neuron death (Crews, 2012; Sofroniew and Vinters, 2010). Since
striatal apoptosis peaks at one-day post METH administration, which precedes glial cell
activation by three days, it is possible that the induced apoptosis subsequently triggers glial cell
reactivation. Thereby it is possible that through attenuating striatal apoptosis, NTR1 agonist
inhibited the subsequent glial cell activation. The activation of glial cells may exert its
neurotoxicity through the production of pro-inflammatory cytokines to further promote the
METH-induced striatal neurodegeneration. Cytokines comprise a significant portion of immuneand neuro-modulatory messengers that can be released by active glial cells (Hanisch, 2002).
Some cytokines promote inflammation (pro-inflammatory) while others reduce inflammation
and promote healing (anti-inflammatory) (Dinarello, 2000). There are 18 cytokines under the
interleukin (IL) class (Dinarello, 2000). Other cytokines are identified due to their biological
functions, as in the case of tumor necrosis factor (TNF). During the process of inflammation,
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genes coding the small mediator molecules are up regulated by inflammatory products,
especially IL-1 and TNF. IL-1 and TNF can then trigger the inflammatory cascade. For example,
they induce chemokine synthesis, iNOS activation, COX-2 followed by NO production,
leukotriene synthesis, and activation of neutrophils. IL-1 also appears to be common in cellular
activity leading to apoptosis. In addition, TNF-α has direct toxic effects on neuronal structures
and myelin, and high levels of TNF-α activation have destructive outcomes (Hanisch, 2002).
Based on the above discussion, we speculated that METH-induced striatal neurotoxicity triggers
the activation of glial cells, which promote the production of pro-inflammatory cytokines that
may further augment neurotoxicity in the striatum. The NTR1 agonist may indirectly attenuate
METH-induced glial cell activation and its subsequent toxic proinflammatory factors through
inhibiting the striatal neuron apoptosis.

In addition to the role of glia in neurotoxicity, Nitric Oxide, the minuscule gas molecule in the
CNS, may also exert function in METH-induced neurotoxicity. NO was first recognized as a
messenger molecule in the CNS in 1988 (Garthwaite et al., 1988). Produced from the amino acid
L-arginine by the members of the NO synthase (NOS) (Calabrese et al., 2007), NO could
disperse from its production site to influence neurotransmission, regulation of blood-vessel tone
and immune responses (Garthwaite and Boulton, 1995). The NOS consists of three isoforms:
neuronal NOS (nNOS); endothelial NOS (eNOS); and inducible NOS (iNOS) (Guix et al., 2005;
Bredt et al., 1999; Dawson et al., 1994). iNOS and nNOS have been found in glial cells and
neurons respectively in the CNS. For example, in the striatum, Somatostatin/nNOS/NPY
interneurons express nNOS (Figueredo-Cardenas et al., 1996), which can be induced by
activation of such interneurons. Levels of iNOS in the CNS are low, but iNOS can be induced in

60

activated glial cells (Peruzzi et al., 2004). A great number of investigations indicate Nitric Oxide
played a significant role in METH-induced neurodegeneration. For example, our lab found that
overproduction of NO induced by endogenous neuropeptides modulated the METH-induced
striatum neurodegeneration. In particular, substance P mediates METH-induced striatal apoptosis
through excessive production of NO by nNOS in Somatostatin/nNOS/NPY interneurons (Zhu et
al., 2006; Wang and Angulo, 2011). Besides, pharmacological inhibition of nNOS in the striatum
also attenuated METH-induced striatal apoptosis (Wang and Angulo, 2011). All these findings
indicate the toxic role of NO in neurodegeneration induced by METH. Initial studies on NOmediated signaling indicated that this molecule interacts with soluble guanylyl cyclase (sGC) by
stimulating its activity (Murad, 2006). The consequent product of cyclic GMP is commonly used
as a biomarker of NO, which can mediate several pathways inside neurons and glial cells
(Murad, 2006; Garthwaite, 1995; Gudi, 1999). In the present study, we observed that NTR1
agonist attenuates METH-induced cGMP accumulation in the striatum to control levels. This
result also suggests that the NTR1 agonist attenuates METH-induced NO accumulation in the
striatum. Since the NTR1 agonist also attenuated METH-induced glial cell activation in the
striatum, it is rational to propose that NTR1 attenuates NO overproduction by inhibiting the
activation of glial cells, inactivating iNOS. Whether the NTR1 agonist modulates NO production
by nNOS in the striatal interneurons requires further investigation. For example, by detecting the
levels of nNOS in the striatum after intrastriatal infusion of NTR1 agonist and antagonist, we
could assess if neurotensin exerts effects on NO production in the striatal interneurons.

Higher concentrations of NO are clearly neurotoxic, so inhibition of NO overproduction by
NTR1 agonist results in lower neurotoxicity levels (Calabrese et al., 2007). NO can induce
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neurotoxicity through react with superoxide anions (O2-, produced by inducible nitric oxide
synthase under inflammatory conditions or neuronal nitric oxide synthase as in the case of
excitotoxicity) to form peroxynitrite (Beckman et al., 1990), which is a strong oxidant that can
affect multiple cell components such as GAPDH, Parkin and matrix metalloproteinase 9 (Pacher
et al., 2007; Beckman and Koppenol, 1996). Peroxynitrite can also induce protein nitration
resulting in damage to cellular components (Radi, 2004). Furthermore, NO has been shown to
activate both the constitutive and inducible isoforms of cyclooxygenase, which are upregulated
in brain cells under pro-inflammatory conditions (Mollace et al., 2005; Mancuso et al., 2007).
During the catalytic cycle of cyclooxygenase, the release of free radicals and formation of
prostaglandins occur, which are both closely related to neuroinflammation that may lead to
neurotoxicity (Mancuso et al., 2007).

In addition to NO neurotoxicity, DARPP32 (Dopamine- and cAMP-regulated phosphoprotein)
was also considered in the context of METH-induced neurotoxicity. Highly concentrated in the
striatal spiny medium-sized neurons, DARPP32 interprets information arriving at dopaminergic
neurons in multiple brain regions, including the striatum, via neurotransmitters including
dopamine, glutamate, neurotensin, NO, GABA and serotonin (Svenningsson et al., 2004;
Svenningsson et al., 2002; Greengard, 2001). These neurotransmitters transduce their signals
through their respective receptors, or, in the case of NO, diffuse into striatal projection neurons.
In addition to these neurotransmitters, psychostimulant drugs of abuse are also found to convey
their signals via the DARPP32 pathway indirectly by enhancing dopamine and glutamate
neurotransmission in the striatum (Greengard, 2001). All these signals projecting into the
striatum projection neurons regulate the phosphorylation of DARPP32 at Thr34, leading
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DARPP32 to become an inhibitor of protein phosphatase 1 (PP1) which controls numerous
physiologically important substrates; they include neurotransmitter receptors, ion pumps and
transcription factors to regulate cell cycle and even programmed cell death (Greengard, 2001).
The physiological significance of the DARPP32-PP1 cascade has been well demonstrated in
DARPP32 knockout mice (Fienberg et al., 1998), in which all behavioral, physiological,
biochemical, pharmacological, and toxicological responses to the psychostimulant drugs of abuse
are either diminished or dramatically attenuated compared to the wild type. These results
demonstrate that DARPP32 participates in psychostimulant-modulated neurotoxicity. Chen and
Chen (2005) also observed METH induced phosphorylation of DARPP32 in the striatum, while
not affecting DARPP32 levels from one hour to four hours after drug administration.

Examining the phosphorylation of DARPP32 at Thr34 modulated by METH and NTR1
activation was a critical aspect of our study. We hypothesized that such phosphorylation may be
affected by NTR1 through regulation of dopamine and glutamate neurotransmission. To that end,
we administrated both NTR1 agonist and NTR1 antagonist followed by METH i.p. injection and
subsequent detection of DARPP32 and p34-DARPP32 in the striatum using western blots. We
found that METH induces phosphorylation of DARPP32 at Thr34 without affecting the level of
DARPP32 in the striatum at one hour after drug administration, which is consistent with Chen
and Chen’s findings. Western blot analysis also indicated that the NTR1 agonist attenuates such
phosphorylation, while the NTR1 antagonist exerts the opposite effect to augment such
phosphorylation. Interestingly, the NTR1 agonist alone also decreases the phosphorylation of
DARPP32 at Thr34, while the NTR1 antagonist itself promotes such phosphorylation. These
data support our hypothesis that NTR1 modulates the DARPP32 phosphorylation pathway
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potentially through dopamine and glutamate neurotransmission. Because inhibition of PP1 by
p34-DARPP-32 may ultimately induce apoptosis, our results suggest that neurotensin’s
protection against apoptosis may also occur by inhibiting this mechanism.

Our laboratory's previous studies demonstrated that striatal neuropeptides play a dynamic
homeostatic role under conditions of excessive and prolonged dopamine accumulation. We have
also shown that several neuropeptides, with the exception of substance P, attenuate the impact of
METH. (Yarosh and Angulo, 2012; Zhu et al., 2006; Afanador et al., 2013; Zhu et al., 2006;
Wang and Angulo, 2011) For example, exposure to METH increases the levels of preproNPY
mRNA in the striatum, suggesting an increased use of this neuropeptide (Yarosh and Angulo,
2012), and this neuropeptide Y (NPY), synthesized by striatal interneurons, which encompass
less than 1% of all striatal neurons (Figueredo-Cardenas et al., 1996; Kawaguchi, 1997;Kubota et
al., 1993). In addition, genetic and pharmacological studies demonstrate that NPY counters the
damaging effects of METH, protecting striatal neurons from this psychostimulant (Wilson et al.,
1996; Zhu et al., 2006). Another neuropeptide, somatostatin, is also synthesized by the same
population of striatal interneurons producing NPY (Figueredo-Cardenas et al., 1996). Our
laboratory recently reported that somatostatin also counters the damaging effects of METH,
protecting striatal neurons from METH-induced apoptosis (Afanador et al., 2013). Furthermore,
substance P, a neuropeptide synthesized by striatal spiny projection neurons, augments
production of NO, which further augments METH-induced striatal apoptosis through NK1R
receptor in Somatostatin/nNOS/NPY interneurons (Zhu et al., 2006; Wang and Angulo, 2011).
Thus, neuropeptides, the endogenous agents expressed and utilized in the healthy striatum,
modulate dopaminergic responses under physiological homeostatic conditions as well as in
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aberrant states involving a surfeit of dopamine, as induced by METH. These studies
demonstrated that striatal neuropeptides are strategically positioned to modulate striatal
dopaminergic responses. Although dopamine plays a critical role, there are currently no available
drugs that target neurotoxicity induced by METH. Therefore, it is essential to identify
compounds that modulate dopamine neurotransmission such as neuropeptide neurotensin. In the
present study, we demonstrated that neurotensin modulates METH-induced apoptosis in the
striatum through diverse pathways.

In summary, our data indicate that neurotensin can modulate METH-induced striatal neuron
apoptosis independent of, and in addition to, body temperature regulation. In particular, through
systemic delivery, the NTR1 agonist, PD149163, prevented METH-induced elevation of core
body temperature. Through intrastriatal infusion, however, PD149163 maintained its effect of
attenuating METH-induced striatal apoptosis without affecting body temperature. We also found
that the NTR1 agonist attenuates METH-induced striatal apoptosis through diverse mechanisms
including glial cell activation, DARPP32 phosphorylation, and NO accumulation in the striatum.
Each of these factors may interact with each other to exert the overall protective effect against
METH-induced neurodegeneration. For example, glial cell activation induces the production of
NO, which promotes the DARPP32 phosphorylation through NO-cGMP-PKG pathway. NO
accumulation and glial cell activation may also induce striatal apoptosis through reacting with
reactive oxygen species and toxic proinflammatory factors in addition to the DARPP32
phosphorylaiton pathway. The potential mechanism model of neurotensin modulating METHinduced neurotoxicity in the striatum is summarized in figure 16. Based upon these findings,
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PD149163 may serve as a suitable candidate for further investigation as a neuroprotective agent
in the brain.
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Figure 16. Mechanism model of neurotensin attenuating METH-induced striatal
neurodegeneration. Neurotensin is bio-synthesized by the striatal medium spiny neurons
(MSNs) and secreted inside the striatum, where neurotensin receptor 1 is the principal
neurotensin receptor located in both dopamine terminal and corticostriatal neurons. Neurotensin
release is up-regulated by METH administration inside the striatum as shown above. Once
activated, NTR1 can enhance the neurotransmission of dopamine and glutamate through reaction
with D1/D2 dopamine receptor and NMDA receptor both localized on the membrane of striatal
MSNs. Activation of D1 receptor will promote phosphorylation of DARPP32 while NMDA
receptor and D2 receptor function to dephosphorylate DARPP32. In addition to dopamine and
glutamate neurotransmission modulation, the NTR1 agonist also attenuates METH-induced NO
and cGMP accumulation in the striatum. Effect of NTR1 on dopamine, glutamate and NO
neurotransmission all potentially modulate DARPP32 phosphorylation as evidenced by the fact
that NTR1 agonist attenuates phosphorylation of DARPP32 while NTR1 antagonist reverses
such effect. Besides, NTR1 activation also attenuates METH-induced glial cell activation and
hyperthemia. NTR1 agonist can attenuate METH-induced striatal apoptosis independent of body
temperature regulation.
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